CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a new treatment for Inflammatory Bowel Disease (IBD) using selective activators of the Farnesoid X nuclear Receptor and creating a non-invasive diagnostic tool based on gut microbiome changes. It aims to enhance patient care through innovative therapies and diagnostics.
Inflammatory Bowel Disease (IBD) covers a cluster of disorders characterized by chronic intestinal inflammation which affects approximately 0.2% of the global human population.
Current treatment options often fail, are marred by side-effects and undergoing regular endoscopy to monitor and manage the disease is often a burden to the patient.In this study we aim to:1.
Develop a novel treatment for IBD, using the recently described anti-inflammatory effects of agonists capable of selectively activa…
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, Perugia
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
France, PARIS
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
